Preconditioning Enhances the Therapeutic Effects of Mesenchymal Stem Cells on Colitis Through PGE2-Mediated T-Cell Modulation

• Published in: Cell transplantation Vol. 27; no. 9; pp. 1352 - 1367
• Main Authors: Yang, Fu Yuan, Chen, Rui, Zhang, Xiaohu, Huang, Biao, Tsang, Lai Ling, Li, Xican, Jiang, Xiaohua
• Format: Journal Article
• Language: English
• Published: Los Angeles, CA SAGE Publications 01.09.2018; Sage Publications Ltd; SAGE Publishing
• Subjects: Animals; Apoptosis; Body weight; Cell activation; Cell culture; Cell differentiation; Cell Line; Cell migration; Cell proliferation; Cell survival; Colitis; Colitis - immunology; Colitis - pathology; Colitis - therapy; Developmental stages; Dinoprostone - immunology; Female; HCT116 Cells; Humans; Immunological diseases; Immunomodulation; Immunoregulation; Inflammatory bowel disease; Inflammatory bowel diseases; Inflammatory Bowel Diseases - immunology; Inflammatory Bowel Diseases - pathology; Inflammatory Bowel Diseases - therapy; Interleukin 10; Intestine; Jurkat Cells; Lymphocytes T; Mesenchymal Stem Cell Transplantation - methods; Mesenchymal stem cells; Mesenchymal Stem Cells - immunology; Mesenchyme; Metabolic pathways; Mice, Inbred C57BL; Original; Prostaglandin E2; T-Lymphocytes - immunology; Tumor necrosis factor-TNF; Tumor necrosis factor-α; Umbilical cord; PGE2; MSCs; IBD; immune; Preconditioning

Mesenchymal stem cell (MSC)-based cell therapy has been demonstrated as a promising strategy in the treatment of inflammatory bowel disease (IBD), which is considered an immune disease. While the exact mechanisms underlying the therapeutic effect of MSCs are still unclear, MSCs display anti-inflamma...